A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles

Abstract Monoclonal antibodies have deserved a remarkable interest for more than 40 years as a vital tool for the treatment of various diseases. Still, there is a raising interest to develop advanced monoclonal antibody delivery systems able to tailor pharmacokinetics. Bevacizumab is a humanized imm...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Flávia Sousa, Andrea Cruz, Pedro Fonte, Inês Mendes Pinto, Maria Teresa Neves-Petersen, Bruno Sarmento
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/d53d29d91a274412b03b006cf9a016af
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares